---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-055644"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T12:06:27.235388+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Erasca Q1 net loss $35.0M ($0.23/shr); cash $297.7M; naporafenib data shows 13-14 mo median OS

## Summary
- Net loss $35.0M vs $33.2M YoY; EPS $(0.23) vs $(0.22).
- Cash, equivalents & marketable securities $297.7M as of March 31, 2024.
- Pooled analysis of naporafenib + trametinib shows median OS 13.0-14.1 months in NRASm melanoma.
- Closed oversubscribed $45M private placement in April 2024, extending cash runway into H2 2026.
- Upcoming milestones: Phase 3 SEACRAFT-2 initiation Q2 2024; multiple data readouts in 2024.

## SEC filing metadata
- accession: 0000950170-24-055644
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000095017024055644/0000950170-24-055644-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000095017024055644/eras-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-055644
- JSON: https://secwatch.observer/filing/0000950170-24-055644.json
- Plain text: https://secwatch.observer/filing/0000950170-24-055644.txt

## Key facts
- Earnings Releases
  Erasca, Inc. reported the fiscal quarter ended March 31, 2024 results: net income $35.0 million, EPS $(0.23) per basic and diluted share.
  - Period: the fiscal quarter ended March 31, 2024
  - Net income: $35.0 million
  - EPS: $(0.23) per basic and diluted share
  - Result: reported results
  source text: Net loss was $35.0 million, or $(0.23) per basic and diluted share, for the quarter ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1761918/000095017024055644/0000950170-24-055644-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.